Page 7 - பதில் ரேட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology Triple Class Refractory (n=119) Extra Medullary Disease (n=55) Overall Response Rate (ORR) 4.2 months 5.5 months 8.5 months For more information, please contact: Klaas Bakker, MD, PhD, Chief Medical Officer, Oncopeptides Mail: klaas.bakker@oncopeptides.com E-mail: rein.piir@oncopeptides.com Cell phone: +46 70 853 72 92 The information in this press release was submitted for publication on December 9, 2020 at 22:00 (CET). About melflufen Melflufen (INN melphalan flufenamide) is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload. Aminopeptidases are overexpressed in tumor cells and are even more pronoun

United statesKlaas bakkerDrug administrationNasdaq stockholmNew drug applicationChief medical officerClass refractoryMedullary diseaseResponse rateProgression free survivalOverall survivalInvestor relationsAdverse eventsMid capClinical oncologyஒன்றுபட்டது மாநிலங்களில்